Fig. 7: NETs-associated markers serve as prognostic risk factors.

A The levels of NETs-associated markers in plasma of patients with (n = 31) or without AAEs (n = 85) after endovascular treatment (p < 0.001; p = 0.3505; p = 0.0207; p = 0.5449; p = 0.5294, p = 0.6997, respectively). B ROC curve analysis showing that at the cut-off level defined as 6.91 ng/ml CitH3, the sensitivity and specificity for predicting AAEs are 0.6 and 0.9, respectively, with the area under the curve of 0.75. C Pie chart displaying the frequencies for combinations of levels of CitH3 (split into categorical variable) and prognostic status (whether patients developed AAEs). D The univariable and multivariable Cox regression models showing that CitH3 and IL-1β were independent risk factors for AAEs of patients with AD. The upper- and lower-line segment indicating the 95% confidence interval. (E) Kaplan-Meier curves of patients with high levels of CitH3 (≥6.91 ng/ml) and the incidence of AAEs compared to patients with low levels of CitH3 (<6.91 ng/ml). Below the survival curves showing the number of exposed subjects at each time point. F Kaplan–Meier curves of patients with high IL-1β (≥90.86 pg/ml) and the incidence of AAEs compared to patients with low IL-1β (<90.86 pg/ml). Below the survival curves showing the number of exposed subjects at each time point. Values are expressed as means ± SD. Source data are provided as a Source Data file. A two-sided statistical significance was set at *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Mann–Whitney U test. ROC: receiver operating characteristic.